220 likes | 321 Views
Explore the collateral damage and rejection treatments during the first year of deceased donor kidney transplants due to HLA mismatching. Discover significant findings on rejection rates, steroid doses, Non-Hodgkin Lymphoma risks, osteoporosis, hip fractures, graft survival, causes of death, and the impact of HLA mismatches.
E N D
CollateralDamageFrom HLA Mismatching Gerhard Opelz
Rejection Treatment During 1stYearDeceasedDonorKidneyTransplants 1990-2012 +84%
Rejection Treatment During 1st Year A+B Mismatches 0 DR MM DR Mismatches 0 A+B MM +97% +57%
Steroid Dose at Year 1 (mg/kg/d) A+B Mismatches 0 DR MM DR Mismatches 0 A+B MM
*) > 90-Percentile Transplantation 89: 567-572, 2010
Non-Hodgkin LymphomaDeceasedDonorKidneyTransplants HLA-A HLA-B HLA-DR Transplantation 89: 567-572, 2010
Non-Hodgkin Lymphoma – EBV StatusKidneyTransplants 1995-2012 Transplantation 88: 962-67, 2009
Pediatric Recipients Transplantation 90: 292-297, 2010
Osteoporosisat Year 5 +50% Transplantation 91: 65-69, 2011
Hip Fracture +170% Transplantation 91: 65-69, 2011
Death With a Functioning GraftDeceasedDonorKidneyTransplants n=177,584 2% per year 5%
Death With a Functioning Graft Am J Transplant 12: 3031-3038, 2012
Causeof Death Infection Cardiovascular Cancer Am J Transplant 12: 3031-3038, 2012
Death With a Functioning Graft Am J Transplant 12: 3031-3038, 2012